CYP2C19 genotype status and cure rates for H-pylori infection with rabeprazole plus amoxicillin.

被引：0
|
作者：
Ohashi, K
Furuta, T
Shirai, N
Kosuge, K
Watanabe, H
Ishizaki, T
机构：
[1] Kumamoto Univ, Dept Pharmacol Ther, Kumamoto, Japan
[2] Hamamatsu Univ Sch Med, Dept Internal Med 1, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Clin Pharmacol, Hamamatsu, Shizuoka, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OIIA1
引用
收藏
页码：140 / 140
页数：1
相关论文
共 50 条
  • [41] Nocturnal acid inhibition by different dosing schemes of rabeprazole in relation to CYP2C19 genotype
    Sugimoto, M
    Furuta, T
    Shirai, N
    Kajimura, M
    Sakurai, S
    Ohashi, K
    Ishizaki, T
    GASTROENTEROLOGY, 2004, 126 (04) : A335 - A336
  • [42] CYP2C19 genotype does not have a significant pharmacokinetic influence in sodium rabeprazole.
    Aoyama, N
    Sakai, T
    Sakaeda, T
    Shirasaka, D
    Miyamoto, M
    Kasuga, M
    GASTROENTEROLOGY, 2000, 118 (04) : A1211 - A1211
  • [43] Hp-normogram (normo-graham) for Assessing the Outcome of H-pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype
    Graham, David Y.
    HELICOBACTER, 2016, 21 (02) : 85 - 90
  • [44] Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection
    Sugimoto, M
    Furuta, T
    Shirai, N
    Nakamura, A
    Kajimura, M
    Sugimura, H
    Hishida, A
    Ishizaki, T
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (10) : 1033 - 1040
  • [45] Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19
    Okudaira, K
    Furuta, T
    Shirai, N
    Sugimoto, M
    Miura, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 491 - 497
  • [46] Influence of single nucleotide polymorphisms of CYP2C19 and 23s rRNA of H-pylori determined from gastric mucosal samples on response to a triple therapy for H-pylori infection
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Kodaira, M
    Kajimura, M
    Ohashi, K
    Ishizaki, T
    Hishida, A
    GASTROENTEROLOGY, 2005, 128 (04) : A426 - A426
  • [47] Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes
    Miura, M
    Kagaya, H
    Tada, H
    Uno, T
    Yasui-Furukori, N
    Tateishi, T
    Suzuki, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 315 - 320
  • [48] Influence of CYP2C19 polymorphism and helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection
    Furuta, T
    Sagehashi, Y
    Shirao, N
    Sugimoto, M
    Nakamura, A
    Kodaira, M
    Kenmotsu, K
    Nagano, M
    Egashira, T
    Ueda, K
    Yoneyama, M
    Ohashi, K
    Ishizaki, T
    Hishida, A
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (06) : 564 - 573
  • [49] Rabeprazole experience in Korea;: focus on CYP2C19 polymorphism
    Park, SH
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 : S20 - S21
  • [50] The effect of CYP2C19 polymorphisms on H-pylori eradication rates with PPI dual and triple first line therapies -: a meta-analysis.
    Padol, S
    Yuan, YH
    Thabane, M
    Padol, IT
    Hunt, RH
    GASTROENTEROLOGY, 2005, 128 (04) : A430 - A430
12345